Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry

Published:September 02, 2021DOI:


      • This study evaluates long term vision and other neurologic outcomes in patients presenting with optic neuritis (ON)
      • MSBase represents a large, diverse, international group of MS patients
      • Most participants had good visual acuity several years after acute ON
      • Treatment with MS therapies was associated with lower risk of conversion to MS and improved neurological/visual function



      Short-term outcomes of optic neuritis (ON) have been well characterized. Limited data exists on longer-term visual outcomes in patients who present with ON. The large MSBase registry allows for characterization of long-term visual outcomes after ON.


      Via the MSBase Registry, data on patients from 41 centers was collected during routine clinical and research visits. Physical and visual disability were measured using the expanded disability status scale (EDSS) and the visual function score (VFS). Inclusion criteria for this analysis included age ≥ 18 years, clinically isolated syndrome (CIS), ON-onset, baseline visit within 6 months of onset, and at least one follow-up visit. Survival analysis was used to evaluate the association of disease-modifying treatment with time to conversion to clinically definite MS or sustained EDSS/VFS progression.


      Data from 60,933 patients were obtained from the MSBase registry in July 2019. Of these, 1317 patients met inclusion criteria; 935 were treated at some point in disease course, while 382 were never treated. At baseline, mean age was 32.3 ± 8.8 years, 74% were female, median EDSS was 2 (IQR 1–2), and median VFS was 1 (IQR 0–2). Median follow-up time was 5.2 years (IQR 2.4–9.3). Treatment was associated with reduced risk and delayed conversion to clinically definite MS (HR = 0.70, p < 0.001), sustained EDSS progression (HR = 0.46, p < 0.0001) and sustained VFS (HR = 0.41, p < 0.001) progression.


      In the MSBase cohort, treatment after ON was associated with better visual and neurological outcomes compared to no treatment. These results support early treatment for patients presenting with ON as the first manifestation of MS.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Group ONS
        Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial.
        Ophthalmology. 2008; 115 (e1075): 1079-1082
        • Brown J.W.L.
        • Coles A.
        • Horakova D.
        • et al.
        Association of Initial Disease-Modifying Therapy with Later Conversion to secondary progressive multiple sclerosis.
        Jama. 2019; 321: 175-187
        • Tsivgoulis G.
        • Katsanos A.H.
        • Grigoriadis N.
        • et al.
        The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis.
        Ther. Adv. Neurol. Disord. 2015; 8: 193-202
        • Wilhelm H.
        • Schabet M.
        The Diagnosis and Treatment of Optic Neuritis.
        (Deutsches Aerzteblatt Online)2015
        • Butzkueven H.
        • Chapman J.
        • Cristiano E.
        • et al.
        MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis.
        Mult. Scler. 2006; 12: 769-774
        • Kalincik T.
        • Butzkueven H.
        The MSBase registry: Informing clinical practice.
        Multiple Sclerosis (Houndmills, Basingstoke, England). 2019; 14 (Epub 2019 May 23. PMID: 31120376): 1828-1834
        • Neurostatus Training [online]
        (Available at:)
        • Kurtzke J.F.
        Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
        Neurology. 1983; 33: 1444-1452
        • SankeyMATIC (BETA) [online]
        (Available at:) (Accessed 03/09/2021)
        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • et al.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; 17: 162-173
        • Filippi M.
        • Rocca M.A.
        • Ciccarelli O.
        • et al.
        MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
        Lancet Neurol. 2016; 15: 292-303
        • Beck R.W.
        • Cleary P.A.
        • Backlund J.C.
        The course of visual recovery after optic neuritis. Experience of the optic neuritis treatment trial.
        Ophthalmology. 1994; 101: 1771-1778
        • Gal R.L.
        • Vedula S.S.
        • Beck R.
        Corticosteroids for treating optic neuritis.
        Cochrane Database Syst. Rev. 2015 Aug 14; 2015 (PMID: 26273799; PMCID: PMC4730547)
        • Kister I.
        • Bacon T.E.
        • Chamot E.
        • et al.
        Natural history of multiple sclerosis symptoms.
        Int. J. MS Care. 2013; 15: 146-158
        • Sabadia S.B.
        • Nolan R.C.
        • Galetta K.M.
        • et al.
        20/40 or better visual acuity after optic neuritis: not as good as we once thought?.
        J. Neuro-Ophthalmol. 2016; 36: 369-376
        • Balcer L.J.
        • Raynowska J.
        • Nolan R.
        • et al.
        Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.
        Multiple Sclerosis (Houndmills, Basingstoke, England). 2017; 23: 734-747
        • Baier M.L.
        • Cutter G.R.
        • Rudick R.A.
        • et al.
        Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
        Neurology. 2005; 64: 992-995
        • Balcer L.J.
        • Galetta S.L.
        • Calabresi P.A.
        • et al.
        Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
        Neurology. 2007; 68: 1299-1304
        • Kalincik T.
        • Kuhle J.
        • Pucci E.
        • et al.
        Data quality evaluation for observational multiple sclerosis registries.
        Multiple Sclerosis (Houndmills, Basingstoke, England). 2017; 23: 647-655